Evinacumab

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Evinacumab
   1. Pharmacist Assessment Report
   2. Evinacumab: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Evinacumab: Known uses and market status in Canada

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Evinacumab, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	1
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
hypercholesterolemia	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Canada Market Information

Licence	Product	Dosage form	Status
02541769	EVKEEZA		Valid

Safety Considerations

Please refer to the package insert for safety information. No warnings, contraindications or drug interaction records were available in the data compiled for this report.

For any eye-related use, evinacumab is a systemically given antibody, so how well it reaches the eye, the route of delivery and its safety in that setting would all need investigation.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---